Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07051629 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
A Phase 1 study of Epilepsy and Healthy Volunteer, sponsored by Suninflam.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 2
- Study locations
NCT07051629 is a Phase 1 study of Epilepsy and Healthy Volunteer that is actively recruiting participants, run by Suninflam. The registered enrollment target is 72 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT07051629, a Phase 1 study of Epilepsy and Healthy Volunteer, is actively recruiting participants, sponsored by Suninflam.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL SIF001
Study Locations (2)
Florida
- Accel Research sites network - DeLand
Michigan
- Quest Research Institute - Farmington Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-06-16 |
| Est. Completion | 2027-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07051629
The ClinicalTrials.gov registry entry for NCT07051629 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (92% lower). The listed sponsor is Suninflam, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07051629 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT07051629 about?
NCT07051629 is a clinical study titled "Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients". This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy
What is the current status of trial NCT07051629?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2025-06-16. Estimated completion is 2027-03-15.
What conditions does trial NCT07051629 study?
This clinical trial studies the following conditions: Epilepsy, Healthy Volunteer.
What interventions are being tested in trial NCT07051629?
The interventions under investigation include: Placebo (DRUG), SIF001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07051629?
This trial is sponsored by Suninflam, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07051629 being conducted?
This trial has 2 study locations across Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Understanding Ketamine's Dissociative Effects (KD Study)
RECRUITING · Phase 1
-
A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy
RECRUITING · Phase 1
-
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
RECRUITING · Phase 1
-
Microelectrode Recordings From the Vagus Nerve in Awake Humans
RECRUITING · Phase 1
-
Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.